Literature DB >> 33271969

Extra-Intestinal Effects of C. difficile Toxin A and B: An In Vivo Study Using the Zebrafish Embryo Model.

Federica Tonon1, Stefano Di Bella1, Gabriele Grassi2, Roberto Luzzati1, Paolo Ascenzi3, Alessandra di Masi3, Cristina Zennaro1.   

Abstract

C.difficile infection (CDI) is not a merely "gut-confined" disease as toxemia could drive the development of CDI-related extra-intestinal effects. These effects could explain the high CDI-associated mortality, not just justified by diarrhea and dehydration. Here, the extra-intestinal effects of toxin A (TcdA) and B (TcdB) produced by C. difficile have been studied in vivo using the zebrafish embryo model. Noteworthy, protective properties of human serum albumin (HSA) towards toxins-induced extra-intestinal effects were also addressed. Zebrafish embryos were treated with TcdA, TcdB and/or HSA at 24 h post-fertilization. Embryos were analyzed for 48 h after treatment to check vital signs and morphological changes. Markers related to cardio-vascular damage and inflammation were evaluated by Real-Time quantitative PCR and/or western blotting. Both toxins induced cardiovascular damage in zebrafish embryos by different mechanisms: (i) direct toxicity (i.e., pericardial edema, cardiac chambers enlargement, endothelial alteration); (ii) increased hormonal production and release (i.e., atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP)), (iii) alteration of the vascular system through the increase of the vascular endothelial growth factor (VEGF-A) levels, as well as of its receptors, (iv) pro-inflammatory response through high cytokines production (i.e., CXCL8, IL1B, IL6 and TNFα) and (v) cell-mediated damage due to the increase in neutrophils number. In addition to cardiovascular damage, we observe skin alteration and inflammation. Finally, our data indicate a protective effect of HSA toward the toxins induced extra-intestinal effects. Together, our findings can serve as a starting point for humans' studies to substantiate and understand the extra-intestinal effects observed in CDI patients.

Entities:  

Keywords:  C. difficile infection; toxins; zebrafish

Mesh:

Substances:

Year:  2020        PMID: 33271969      PMCID: PMC7760802          DOI: 10.3390/cells9122575

Source DB:  PubMed          Journal:  Cells        ISSN: 2073-4409            Impact factor:   6.600


  45 in total

1.  The Protective Role of Albumin in Clostridium difficile Infection: A Step Toward Solving the Puzzle.

Authors:  Stefano Di Bella; Alessandra di Masi; Simona Turla; Paolo Ascenzi; Theodore Gouliouris; Nicola Petrosillo
Journal:  Infect Control Hosp Epidemiol       Date:  2015-10-12       Impact factor: 3.254

2.  VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain.

Authors:  N van Bruggen; H Thibodeaux; J T Palmer; W P Lee; L Fu; B Cairns; D Tumas; R Gerlai; S P Williams; M van Lookeren Campagne; N Ferrara
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

3.  The association between pneumococcal pneumonia and acute cardiac events.

Authors:  Daniel M Musher; Adriana M Rueda; Anjum S Kaka; Sulaiman M Mapara
Journal:  Clin Infect Dis       Date:  2007-06-06       Impact factor: 9.079

4.  Meta-analysis to assess risk factors for recurrent Clostridium difficile infection.

Authors:  K W Garey; S Sethi; Y Yadav; H L DuPont
Journal:  J Hosp Infect       Date:  2008-10-31       Impact factor: 3.926

5.  Extraintestinal Clostridium difficile infections.

Authors:  Eero Mattila; Perttu Arkkila; Petri S Mattila; Eveliina Tarkka; Päivi Tissari; Veli-Jukka Anttila
Journal:  Clin Infect Dis       Date:  2013-06-13       Impact factor: 9.079

Review 6.  Zebrafish as a model host for streptococcal pathogenesis.

Authors:  Jesse D Miller; Melody N Neely
Journal:  Acta Trop       Date:  2004-06       Impact factor: 3.112

7.  Cardiac myocyte dysfunction induced by streptolysin O is membrane pore and calcium dependent.

Authors:  Devin D Bolz; Zhi Li; Eric R McIndoo; Rodney K Tweten; Amy E Bryant; Dennis L Stevens
Journal:  Shock       Date:  2015-02       Impact factor: 3.454

8.  Podocyte developmental defects caused by adriamycin in zebrafish embryos and larvae: a novel model of glomerular damage.

Authors:  Cristina Zennaro; Massimo Mariotti; Michele Carraro; Sara Pasqualetti; Alessandro Corbelli; Silvia Armelloni; Min Li; Masami Ikehata; Milan Clai; Mary Artero; Piergiorgio Messa; Giuliano Boscutti; Maria Pia Rastaldi
Journal:  PLoS One       Date:  2014-05-20       Impact factor: 3.240

Review 9.  Endothelial Contributions to Zebrafish Heart Regeneration.

Authors:  Cristina E Fernandez; Melanie Bakovic; Ravi Karra
Journal:  J Cardiovasc Dev Dis       Date:  2018-12-11

Review 10.  Does Bacillus anthracis Lethal Toxin Directly Depress Myocardial Function? A Review of Clinical Cases and Preclinical Studies.

Authors:  Dante A Suffredini; Hanish Sampath-Kumar; Yan Li; Lernik Ohanjanian; Kenneth E Remy; Xizhong Cui; Peter Q Eichacker
Journal:  Toxins (Basel)       Date:  2015-12-12       Impact factor: 4.546

View more
  2 in total

1.  Human α-Defensin-6 Neutralizes Clostridioides difficile Toxins TcdA and TcdB by Direct Binding.

Authors:  Lara Barthold; Sebastian Heber; Christoph Q Schmidt; Marion Gradl; Gilbert Weidinger; Holger Barth; Stephan Fischer
Journal:  Int J Mol Sci       Date:  2022-04-19       Impact factor: 6.208

2.  5-Azacytidine Downregulates the Proliferation and Migration of Hepatocellular Carcinoma Cells In Vitro and In Vivo by Targeting miR-139-5p/ROCK2 Pathway.

Authors:  Federica Tonon; Maja Cemazar; Urska Kamensek; Cristina Zennaro; Gabriele Pozzato; Sergio Caserta; Flora Ascione; Mario Grassi; Stefano Guido; Cinzia Ferrari; Laura Cansolino; Francesco Trotta; Biljana Grcar Kuzmanov; Giancarlo Forte; Fabiana Martino; Francesca Perrone; Riccardo Bomben; Valter Gattei; Nicola Elvassore; Erminio Murano; Nhung Hai Truong; Michael Olson; Rossella Farra; Gabriele Grassi; Barbara Dapas
Journal:  Cancers (Basel)       Date:  2022-03-23       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.